Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

0.3462
Delayed Data
As of Jun 08
 -0.0138 / -3.83%
Today’s Change
0.30
Today|||52-Week Range
1.60
-34.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$17.8M

Company Description

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Contact Information

Zynerba Pharmaceuticals, Inc.
80 West Lancaster Avenue
Devon Pennsylvania 19333
P:(484) 581-7505
Investor Relations:
(484) 581-7483

Employees

Shareholders

Individual stakeholders7.36%
Mutual fund holders7.06%
Other institutional5.06%

Top Executives

Armando AnidoChairman & Chief Executive Officer
Terri B. SebreePresident
James E. FickenscherChief Financial Officer & VP-Corporate Development
Nancy TichVice President-Clinical
Stephen O'QuinnVice President-Medical Affairs